Macquarie tips 28% upside for this ASX healthcare stock

The broker expects big things from this New Zealand retirement village developer and operator.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investor interest in ASX healthcare stocks has climbed recently. The S&P/ASX 200 Healthcare Index (ASX: XHJ) dropped overall in FY25 but appears to have made some recovery so far in July.

As of lunchtime today, the index is 0.89% higher and has climbed 1.28% over the past five days. For the year to date, the index is 9.26% higher.

And continued momentum and strong potential upside for one ASX healthcare stock could drive the sector higher.

Summerset Group Holdings Ltd (ASX: SNZ) shares are flat at $11.00 as of midday today but have jumped 30.49% over the year. Over the past three months, the New Zealand retirement village developer and operator's share price has climbed 11.22%.

Here's what Macquarie Group Ltd (ASX: MQG) thinks of the stock.

An older gentleman leans over his partner's shoulder as she looks at a tablet device while seated at a table.

Image source: Getty Images

Macquarie revises Summerset Group's target price

Macquarie maintains its outperform rating on Summerset Group and has raised its target price to NZ$15.75, up from NZ$15.35. As of midday today, the company's shares are trading at NZ$12.02.

The revised target price represents a potential 28% upside for the stock.

The company is dual-listed on the ASX and the NZX, which means local Australian investors could also benefit from any potential upside.

In a note to investors, the broker said the company's new sales reached a record volume in Q2 2025, up 42% compared with the previous corresponding period, and 68% higher than Q1.

Total sales for the first half of 2025 are 22% higher period-on-period, making it a record half-yearly result for the business. 

Summerset Group has seen "road-based improvement in sales and noted uncontracted new stock decreased 6% in the period and contracted stock increased by 50%."

"Australia saw 9 sales over the period, in line with FY24 contracts."

The company's resales volumes also meant it achieved the best Q2 on record and the second-best quarter overall. 

"A combination of offering, improved housing market, competitor disruptions and sales team effectiveness is underpinning strong sales and contracting will drive 2H25 growth. Upside risk to FY25 earnings is emerging, while SUM's overall growth outlook remains attractive," the broker said in its investor note. 

"Key risks include quantum and speed of improvement in housing market conditions, and associated impact on sales including St Johns. Success and speed of ramp-up in Australia is a key driver of growth in the medium to long term."

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Macquarie Group. The Motley Fool Australia has positions in and has recommended Macquarie Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

smiling health care workers in a medical setting
Share Market News

3 ASX healthcare shares to buy amid sector rout: experts

Healthcare shares have tumbled 36% over the past year amid multiple headwinds for the sector.

Read more »

Person pressing the buy button on a smartphone.
Broker Notes

3 reasons to buy Pro Medicus shares today

A leading analyst believes Pro Medicus shares are now trading at a significant discount.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Healthcare Shares

This ASX biotech has just announced a major US deal

This company's heart disease technology is gaining traction.

Read more »

Devastated woman sits near smartphone on home kitchen floor troubled with loneliness.
Healthcare Shares

Which beaten down ASX healthcare stock is a better buy right now: Pro Medicus vs Cochlear shares

Which do experts prefer?

Read more »

Health professional working on his laptop.
Healthcare Shares

Already up 42% this year, Morgans says this ASX healthcare stock can continue to rocket

This broker sees big upside for this healthcare stock.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Healthcare Shares

This ASX small-cap healthcare stock could rocket more than 50%: Morgans

Share price weakness could present an opportunity.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

Guess which ASX 300 stock was given a big boost from the US FDA

This healthcare stock has made a positive announcement today.

Read more »

A man in a business suit rides a graphic image of an arrow that is rebounding on a graph.
Broker Notes

Down 43% this week, are Cochlear shares now the best bargain buy of the year?

A leading analyst believes the historic selloff in Cochlear shares could present a unique buying opportunity.

Read more »